Advertisement

Rheumatology International

, Volume 32, Issue 11, pp 3397–3403 | Cite as

Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis

  • Shengqian Xu
  • Yu Wang
  • Jingqiu Lu
  • Jianhua XuEmail author
Original Article

Abstract

Osteoporosis represents an important cause of morbidity in adult rheumatoid arthritis (RA) patients who exhibit increased fracture risk. It is thought that osteoclast and its dysfunction which mediated by many cytokines are the principal pathogenesis of this bone disease, although the mechanisms are still not fully understood. Osteoprotegerin (OPG) and receptor activator of nuclear factor-kappa B ligand (RANKL) have been revealed in the pathogenesis of primary osteoporosis and other metabolic bone diseases. Thus, the aim of this study was to investigate the possible role of the OPG/RANKL system in RA-related bone loss. A total of 64 Chinese patients with RA and 60 healthy control subjects were involved. Serum levels of OPG and RANKL were measured by ELISA. BMD of nondominant forearm, lumbar spine(L1–4) and proximal femur, including femoral neck, Wards triangle, greater trochanter were assessed using dual-energy X-ray absorptiometry. RA patients had a higher incidence of osteoporosis (23/64, 35.9%) than that in healthy controls (9/60, 15.0%) (P < 0.0001). They displayed lower BMD values than controls at positions of all detected region. Compared with healthy controls, RA group showed significantly higher serum levels of RANKL (48.4 ± 12.5 vs. 23.0 ± 11.2 pmol/l, P < 0.0001), lower serum levels of OPG (106.2 ± 40.6 vs. 231.6 ± 65.6 pg/ml, P < 0.0001), and OPG/RANKL ratio (2.4 ± 0.7 vs. 7.0 ± 1.1, P < 0.0001). Multiple linear regression analysis revealed that in RA group, plasma rheumatoid factor concentration (β = −0.187, P = 0.031), swollen joint count (β = 0.567, P = 0.029), BMD at forearm (β = 0.324, P = 0.002), femoral Wards triangle (β = 0.370, P < 0.0001), and lumbar spine (β = 0.313, P = 0.003) were the contributors for serum OPG (R 2  = 0.718, P < 0.0001). Age (β = 0.241, P = 0.042) and BMD at femoral Wards triangle (β = −0.441, P < 0.0001) and lumbar spine (β = −0.320, P = 0.013) were the determinants for serum RANKL (R 2  = 0.616, P < 0.0001), while swollen joint count (β = 1.029, P = 0.019) and BMD at femoral neck (β = 0.285, P = 0.042) for serum OPG/RANKL ratio (R 2  = 0.279, P < 0.011). Analysis of logistic regression showed age (P = 0.004, OR = 1.156, 95% CI: 1.047–1.276) and the level of C-reactive protein (P = 0.028, OR = 1.019, CI 95%: 1.002–1.036) in peripheral blood of RA were the risk factors for the occurrence of osteoporosis in RA, while OPG/RANKL ratio (P = 0.007, OR = 0.035, CI 95%: 0.003–0.400) was the unique protective factor. These data suggest that, in Chinese RA patients, an altered modulation of the OPG/RANKL system resulting in increased RANKL and decreased OPG in peripheral blood, could contribute to the bone loss characteristic and the generation of osteoporosis in these patients. Changes of ratio of OPG/RANKL might be a protective mechanism against the accelerated bone loss in RA.

Keywords

Rheumatoid arthritis Osteoporosis Osteoprotegerin Receptor activator of nuclear factor-kappa B ligand 

Notes

Acknowledgments

We would like to thank all patients and professionals who participated in the study, particularly Mingming Zhang for his kindly help during the lab proc of measuring the levels of OPG, RANKL and BDM.

References

  1. 1.
    Romas E, Gillespie MT, Martin TJ (2002) Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone 30:340–346 (PubMed: 11856640)PubMedCrossRefGoogle Scholar
  2. 2.
    Abu-Amer Y, Abbas S, Hirayama T (2004) TNF receptor type I regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis. J Cell Biochem 93:980–989 (PubMed: 15389885)PubMedCrossRefGoogle Scholar
  3. 3.
    Gravallese EM, Goldring SR (2000) Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 43:2143–2151 (PubMed: 11037873)PubMedCrossRefGoogle Scholar
  4. 4.
    Hofbauer LC, Heufelder AE (2001) The role of osteoprotegerin and receptor activator of nuclear factor κB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 44:253–259 (PubMed: 11229454)PubMedCrossRefGoogle Scholar
  5. 5.
    Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E et al (2000) Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43:250–258 (PubMed: 10693863)PubMedCrossRefGoogle Scholar
  6. 6.
    Saidenberg KN, Con’ado A, Lemeiter D (2004) TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 35:1200–1207 (PubMed:15542046)CrossRefGoogle Scholar
  7. 7.
    Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142:5050–5055 (PubMed:11713196)PubMedCrossRefGoogle Scholar
  8. 8.
    Page G, Miossec P (2005) RANK and RANKL expression as markers of dendritic cell -T cel1 interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum 52:2307–2312 (PubMed:16052586)PubMedCrossRefGoogle Scholar
  9. 9.
    Kostenuik PJ, Shalhoub V (2001) Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 7:613–635 (PubMed:11375772)PubMedCrossRefGoogle Scholar
  10. 10.
    Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T et al (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610–615 (PubMed: 9647741)PubMedCrossRefGoogle Scholar
  11. 11.
    Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C et al (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315–323 (PubMed: 9950424)PubMedCrossRefGoogle Scholar
  12. 12.
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324 (PubMed: 3358796)PubMedCrossRefGoogle Scholar
  13. 13.
    Liu Z, Piao J, Pang L, Qing X, Nan S, Pan Z et al (2002) The diagnostic criteria for primary osteoporosis and the incidence of osteoporosis in China. J Bone Miner Metab 20:181–189 (PubMed: 12115062)PubMedCrossRefGoogle Scholar
  14. 14.
    Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M et al (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337 (PubMed: 11685647)PubMedCrossRefGoogle Scholar
  15. 15.
    Gravallese EM (2002) Bone destruction in arthritis. Ann Rheum Dis 61(Suppl 2):ii84–ii86 (PubMed: 12379632)PubMedGoogle Scholar
  16. 16.
    Sinigaglia L, Varenna M, Girasole G, Bianchi G (2006) Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin North Am 32:631–658 (PubMed: 17288969)PubMedCrossRefGoogle Scholar
  17. 17.
    Bekker PJ, Holloway D, Nakanishi A, Arrighi HM, Leese PT, Dunstan CR (2001) Osteoprotegerin (OPG) has potent and sustained antiresorptive activity in post menopausal women. J Bone Miner Res 16:348–360 (PubMed:11204435)PubMedCrossRefGoogle Scholar
  18. 18.
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R et al (1997) Osteoprotegerina: a noval secreted protein involved in the regulation of bone density. Cell 89:309–319 (PubMed: 9108485)PubMedCrossRefGoogle Scholar
  19. 19.
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176 (PubMed:9568710)PubMedCrossRefGoogle Scholar
  20. 20.
    Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM et al (1997) TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 86:2075–2080 (PubMed:9396779)CrossRefGoogle Scholar
  21. 21.
    Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S et al (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304–309 (PubMed: 10580503)PubMedCrossRefGoogle Scholar
  22. 22.
    Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W et al (2002) High levels of Osteoprotegerin and soluble receptor activator of nuclear factor κ B ligand in serum of rheumatoid arthritis patients and their normalization after anti–tumor necrosis factor α treatment. Arthritis Rheum 46:1744–1753 (PubMed: 12124857)PubMedCrossRefGoogle Scholar
  23. 23.
    Skoumal M, Kolarz G, Haberhauer G, Woloszczuk W, Hawa G, Klingler A (2005) Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int 26:63–69 (PubMed: 15889303)PubMedCrossRefGoogle Scholar
  24. 24.
    Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E et al (2001) Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 44:1003–1012 (PubMed: 11352231)PubMedCrossRefGoogle Scholar
  25. 25.
    Vanderborght A, Linsen L, Thewissen M, Geusens P, Raus J, Stinissen P (2004) Osteopmtegerin and receptor activator of nuclear factor-kappa B ligand mRNA expression in patients with rheumatoid arthritis and healthy controls. J Rheumatol 31:1483–1490 (PubMed: 15290725)PubMedGoogle Scholar
  26. 26.
    Haynes DR, Crotti TN, Capone M, Bain GI, Atkins GJ, Findlay DM (2001) Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 40:623–630 (PubMed: 11426018)CrossRefGoogle Scholar
  27. 27.
    Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M (2002) Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor κB ligand on adult T-cell leukemia cells. Blood 99:634–640 (PubMed: 11781248)PubMedCrossRefGoogle Scholar
  28. 28.
    Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Bone mineral density and frequency of osteoporosis in female patient with rheumatoid arthritis: result from 394 patients in the Olso county rheumatoid arthritis register. Arthritis Rheum 43:522–530 (PubMed: 10728744)PubMedCrossRefGoogle Scholar
  29. 29.
    Urbanek R, Tlustochowicz W, Patola J, Głodzik J (2000) Incidence of osteoporosis in patients with rheumatoid arthritis. Przegl Lek 57:103–107 (PubMed: 10907352)PubMedGoogle Scholar
  30. 30.
    Oelzner P, Franke S, Lehmann G, Eidner T, Müller A, Wolf G et al (2007) Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis relationship with bone mineral density, disease activity and bone turnover. Clin Rheumatol 26:2127–2135 (PubMed: 17541498)PubMedCrossRefGoogle Scholar
  31. 31.
    Lodder MC, de Jong Z, Kostense PJ, Molenaar ET, Staal K, Voskuyl AE et al (2004) Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. Ann Rheum Dis 63:1576–1580 (PubMed: 15547081)PubMedCrossRefGoogle Scholar
  32. 32.
    Saidenberg-Kermanac’h N, Cohen-Solal M, Bessis N, De Vernejoul MC, Boissier MC (2004) Role for osteoprotegerin in rheumatoid inflammation. Joint Bone Spine 71:9–13 (PubMed: 14769514)PubMedCrossRefGoogle Scholar
  33. 33.
    Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, The Denosumab Rheumatoid arthritis Study Group et al (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelvemonth, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58:1299–1309 (PubMed: 18438830)PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Department of Rheumatology and ImmunologyThe First Affiliated Hospital of Anhui Medical UniversityHefeiChina
  2. 2.Department of Internal MedicineAnkang Hospital of Hefei Public Security BureauHefeiChina

Personalised recommendations